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The conjugate 8 was obtained as a result of condensation of 3-hydroxyiminooleanolic
acid morfolide (7) and aspirin in dioxane. Analgesic effect of OAO-ASA (8) for the
range of doses 0.3–300.0 mg/kg (p.o.) was performed in mice using a hot-plate
test. Anti-inflammatory activity was assessed on carrageenan-induced paw edema in
rats for the same range of doses. The conjugate OAO-ASA (8) did not significantly
change locomotor activity of mice, therefore sedative properties of the compound
should be excluded. The compound 8 proved a simple, proportional, dose-dependent
analgesic action and expressed strong anti-inflammatory activity showing a reversed
U-shaped, dose-dependent relation with its maximum at 30.0 mg/kg. After its combined
administration with morphine (MF, 5.0 mg/kg, s.c.) the lowering of antinociceptive
activity was found; however, the interaction with naloxone (NL, 3.0 mg/kg, s.c.) did
not affect the antinociceptive effect of OAO-ASA (8), therefore its opioid mechanism of
action should be rather excluded. After combined administration with acetylsalicylic acid
(ASA, 300.0 mg/kg, p.o.) in hot-plate test, the examined compound 8 enhanced the
antinociceptive activity in significant way. It also shows that rather the whole molecule is
responsible for the antinociceptive and anti-inflammatory effect of the tested compound
8, however, it cannot be excluded that the summarizing effect is produced by ASA
released from the compound 8 and the rest of triterpene derivative. The occurrence of
tolerance for triterpenic derivative 8 was not observed, since the analgesic and anti-
inflammatory effects after chronic administration of the conjugate OAO-ASA (8) was
on the same level as after its single treatment. It seemed that the anti-inflammatory
mechanism of action of OAO-ASA (8) is not simple, even its chronic administration
lowered both blood concentration of IL-6 and mRNA IL-6 expression. However, the
effects of the conjugate OAO-ASA (8) on TNF-α level and mRNA expression were
opposite. Moreover, compound 8 did not change unequivocally mRNA TLR1, and TLR3
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expression. Concluding, the obtained results regarding the antinociceptive and anti-
inflammatory activity of new conjugate of oleanolic acid oxime and acetylsalicylic acid
(OAO-ASA 8) are very interesting, but for explanation of its mechanism of action, more
detailed studies are necessary.
Keywords: triterpenes, oleanolic acid, acyloxyimino derivatives, acetylsalicylic acid, anti-inflammatory activity,
antinociceptive activity, cytokine levels, mRNA expression
INTRODUCTION
Availability and diversity of plant derived therapeutic materials
and broad spectrum of their pharmacological activities causes
scientists to think hard about looking for not only new
chemical compounds included in these plant materials but
also to obtaining of semisynthetic derivatives of known
compounds with proved pharmacological activity. There are
great hopes surrounding triterpenes, a huge group of natural
compounds with such broad spectrum of pharmacological
activity. One of compounds belonging to this group is
oleanolic acid, probably the most widespread triterpene
in plant kingdom. Scientists proved its antihypertensive,
antiatherosclerotic, antioxidant, anticancer, gastroprotective,
hepatoprotective, anti-inflammatory, antidiabetic, and another
kinds of pharmacological activities (Liu, 1995; Somova et al.,
2003; Dzubak et al., 2006; Sultana and Ata, 2008; Pollier and
Goossens, 2012).
There are known some triterpenes, mainly of oleanane,
ursane, and lupane groups, that exhibit antinociceptive and anti-
inflammatory activity (e.g., Otuki et al., 2005a; Aguirre et al.,
2006; Maia et al., 2006b; Saleem, 2009). Promising results were
also obtained for α- and β-amyrin. In tests performed upon mice
and rats, antinociceptive activity of both amyrins was proved.
This activity was probably connected with vanilloid receptors and
opioid mechanism (Oliveira et al., 2005). Antinociceptive activity
was also proved for oleanolic acid, which also has β-amyrin
skeleton. The effectiveness of action of oleanolic acid was also
dependent on the amount of dose and the mechanism was
also connected with vanilloid and opioid receptors (Maia et al.,
2006a).
Oleanolic acid, as many other triterpenes, presents wide
range of pharmacological activities along with low toxicity and
very good tolerance. Because natural compounds exhibit often
relatively low level of biological activity, numerous experiments
are performed in order to obtain semisynthetic derivatives
with higher therapeutic potential and lower toxicity toward
an organism. The biological tests have shown that compounds
having a hydroxyimino group within the molecule of triterpene
belong to a class of the most active species (Lisiak et al.,
2014). Further significant increases of pharmacological activity
of triterpenic derivatives can be obtained by their simple
modification on the route of hydroxyimino function acylation
(Bednarczyk-Cwynar et al., 2012; Kaminskyy et al., 2012). The
additional element that increases pharmacological activity of such
triterpenic derivative can be the C-17 modified carboxyl function.
It is known from many years that conjugate of salicylic acid with
morpholine is a effective anti-inflammatory agent (Thieblot et al.,
1961) so we decided to obtain an oxime of oleanolic acid in which
the =NOH function will be acylated with acetylsalicylic moiety
and the C-17 carboxyl group will be transformed into morpholide
function.
Still scientists have performed many experiments to obtain
new different derivatives of ASA mostly to avoid aspirin-induced
gastrointestinal effects including decreasing the acidity and
increasing the pharmacological activity of the new designed
aspirin-like drugs (Khalikov et al., 2006; Jiang et al., 2010; Huang
et al., 2012; Hussain et al., 2013). Recently, the new hydrophobic
analogs of aspirin were developed showing inhibition of
the production of pro-inflammatory and enrichment of anti-
inflammatory cytokines (Kalathil et al., 2016).
In view of the above mentioned possibilities, the main
aim of this study was to evaluate an acute and subchronic
antinociceptive and anti-inflammatory activity of new ASA
and triterpenic derivative, named as conjugate OAO-ASA
(8), in animal models. Furthermore, in order to determine
the possible contribution of only ASA activity released
from the test compound in rodents, the use of ASA in
complimentary doses to its presence in OAO-ASA was also
performed. Moreover, to evaluate the possible OAO-ASA
anti-inflammatory mechanism of action, its interaction with
ASA or effect on the concentration or mRNA expression of
pro-inflammatory cytokines (IL-6, TNF-α) or toll-like receptors
(TLR1, TLR3) were investigated. Moreover, keeping in mind
the potential opioid mechanism of action of some oleanolic
acid derivatives (Maia et al., 2006b), the interaction of conjugate
OAO-ASA (8) with morphine and opioid antagonist was
assessed.
MATERIALS AND METHODS
Chemicals
All solvents and reagents for synthesis and purification of
triterpenic compounds were pure for analysis grade and
purchased from Sigma–Aldrich or Chempur. Carrageenan and
Tween 80 were purchased from Sigma–Aldrich, USA; morphine
sulfate (morphini sulfas 20 mg/ml) was purchased from Polfarma,
Poland; acetylsalicylic acid from Galfarma, Cracow, Poland,
naloxone hydrochloride (Naloxonum hydrochloricum WZF
0.4 µg/ml) from WZF Polfa S.A., Warsaw, Poland, 0.9% saline
solution was purchased from Fresenius Kabi, Poland. Oleanolic
acid (3β-hydroxyolean-12-en-28-oic acid) was applied as a parent
compound for further chemical transformations. It was isolated
by us from a by-product residue obtained during industrial
production of mistletoe extract.
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Animals
Experiments were performed on male Swiss mice (20–30 g)
and male Wistar rats (250–350 g) housed in controlled room
temperature (20 ± 0.2◦C) and humidity (65–75%) under a 12 h :
12 h light-dark cycle (lights on 7 a.m.). Animals were kept in
groups of 8–10 mice and 4–5 rats in light plastic cages and had
a free access to standard laboratory diet (pellets-Labofeed B) and
tap water in their cages.
The experiments with animals were performed in accordance
with Polish governmental regulations (Dz.U.05.33.289, 2005).
The study was conducted in accordance to ethical guidelines for
investigations of experimental pain in conscious animals and the
study protocol was approved by the Local Ethics Committee of
the Use of Laboratory Animals in Poznan´ (52/2011).
Instruments
Melting points were measured in open capillaries using the Büchi
apparatus. NMR spectra for hydrogen atoms (1H) and for carbon
atoms (13C) were recorded in deuterated chloroform solution
using the Varian Gemini 300 VT apparatus, for frequencies
400 MHz and 100 MHz, respectively, with TMS as an internal
standard. The values for chemical shifts are given in δ, exact
to ±0.01 ppm and ±0.1 ppm, respectively; J-values are given
exact to ±0.1 Hz. The multiplicities of signals in 1H NMR
spectra were marked as follows: s – singlet, d – doublet, t –
triplet, dd – doublet of doublets, td – triplet of doublets, m –
multiplet. Mass spectrum (MS) was recorded using the AMD
402 spectrometer with electroionization. The elucidation of the
chemical structures was based on 1H NMR, 13C NMR, and MS
analysis.
Horizontal locomotor activity of mice after application of
OAO-ASA (8) was evaluated using a licensed activity meter
(Activity Cage, Ugo Basile, Italy). Analgesic activity of conjugate 8
was evaluated with hot-plate method using a Hot-Plate Analgesia
Meter (Ugo Basile, Italy). Anti-inflammatory activity of OAO-
ASA (8) was evaluated using a plethysmometer (Hugo Sachs
Electronic, Germany).
Methods
TLC Analysis
The thin layer chromatography (TLC) analysis (reactions
progress and the level of compounds purity) was conducted on
HPTLC aluminum sheets covered with silica gel 60 F245 (Merck)
and benzene with ethyl acetate in a volume ratio of 4:1 as an
eluent. The chromatograms were visualized by spraying them
with 10% ethanolic solution of sulfuric acid and heating them at
about 110◦C for a few minutes.
Oxime of Oleanolic Acid Morpholide (7) Acylation
with ASA
ASA (2.16 g, 12 mmol) and N,N-dicyclohexylcarbodiimide
(DCC, 3.09 g, 15 mmol) were added to a stirred at room
temperature solution of oxime of oleanolic acid morpholide
(7, 4.8 g, 10 mmol) in dioxane (100 ml). After substrate total
consumption (TLC control) the mixture after reaction was
filtered off. The filtrate was poured into a fivefold volume of water
acidified with HCl. The obtained white precipitate was filtered off,
washed with water, dried and re-precipitated with water from an
ethanolic solution.
3 -(2 -Acetoxy)benzoyloxyiminoolean -12 -en -28 -oic acid
morpholide (OAO-ASA, 8) C43H60N2O6, mol. mass 700.4451,
yield: 96.9%, mp.: 131–137◦C, white powder. 1H NMR: 7.97 (1H,
dd, J = 1.7 and 7.5 Hz, CH3OCO-Ar-COON=C<) and 7.57
(1H, td, J = 1.1 and 7.8 Hz, CH3OCO-Ar-COON=C<) and 7.32
(1H, td, J = 1.1 and 7.6 Hz, CH3OCO-Ar-COON=C<) and
7.13 (1H, dd, J = 0.6 and 8.2 Hz, CH3OCO-Ar-COON=C<),
5.27 (1H, t, J = 3.5 Hz, C12-H), 3.70–3.58 (8H, m, Mor),
3.08 (1H, d, J = 11.4 Hz, C18-Hβ), 2.34 (3H, s, CH3OCO-
Ar-COON=C<), 1.33, 1.18, 1.13, 1.04, 0.93, 0.90 and 0.78
(7 × 3H, 7 × s, 7 CH3 groups); 13C NMR: 176.3 (Cq, C-28),
175.1 (Cq, C-3), 169.6 (Cq, CH3OCO-Ar-COON=C<), 162.0
(Cq, CH3OCO-Ar-COON=C<), 150.6 and 122.8 (2 × Cq,
CH3OCO-Ar-COON=C<), 133.7, 131.2, 125.9, and 124.0
(4 × CH, CH3OCO-Ar-COON=C<), 144.8 (Cq, C-13), 121.3
(CH, C-12), 66.9 × 2, 46.0 and 41.9 (4 × CH2, Mor), 46.2 (Cq,
C-17); 21.0 (CH3, CH3OCO-Ar-COON=C<); Ar, aromatic
ring; Mor, morpholine ring. MS-EI: 700.6 (22.9%, M+).
Analgesic and Anti-inflammatory Activity of
OAO-ASA (8)
In the first step, acute toxicity study of OAO-ASA (8) was
evaluated using orally application for mice, according to OECD
TG 420 (for chemical substances, from January 21, 2001).
Locomotor Activity Test
The tests were done 60 min after OAO-ASA (8) administration
which was given in the dose of 0.3, 3.0, 30.0, and 300.0 mg/kg
(p.o.) dissolved in 5% Tween 80. The data obtained was expressed
as signals corresponding to animal movements for 5 min after
previous 20 min habituation to the activity meter cage. Next,
horizontal locomotor activities of mice was evaluated using the
licensed activity meter.
Analgesic Activity: Hot-Plate Test
Mice were placed on a hot plate apparatus which was heated
to a constant temperature of 52 ± 2◦C. A single dose of
OAO-ASA (8) in the range of 0.3, 3.0, 30.0, and 300.0 mg/kg
were given (p.o.) and the effects were measured at 0.5, 1.0,
1.5, 2.0, and 24 h following the application. For comparative
purposes, morphine (MF, 5.0 mg/kg, s.c.), naloxone (NL,
3.0 mg/kg, s.c.), or acetylsalicylic acid (ASA, 300 mg/kg, p.o.)
alone or together with OAO-ASA (8) was administered to
other groups of mice. Moreover, the study included the effect
of complimentary doses of ASA (0.77 mg/kg, 7.7 mg/kg, and
77.0 mg/kg, p.o.) to its presence in OAO-ASA (8) (3.0 mg/kg,
30.0 and 300.0 mg/kg, respectively). Control animals received
the proper volume of 5% Tween 80 (p.o.) (vehicle for OAO-
ASA and ASA) and 0.9% saline (s.c.) (vehicle for MF and
NL). Using a timer, the latency to respond was observed
with a hind paw lick, hind paw flick, or a jump which was
measured to the nearest 0.1 s. Subsequently, the mouse was
immediately removed from the hot plate and returned to its
home cage. The maximum time of the response was established
as 60 s.
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Anti-inflammatory Test
Skin inflammation was induced in the right hind paw of rats
by the topical application of 2 mg/paw of carrageenan dissolved
in 0.2 ml of 0.9% saline solution. The rear left paw of the rats,
which was used as the control, received the same volume of 0.9%
saline solution. Single doses of OAO-ASA (8), dissolved in 5%
Tween 80, in the range of 0.3, 3.0, 30.0, and 300.0 mg/kg were
given (p.o.) 30 min after carrageenan injection. For comparison,
one group of rats was treated with the single ASA (200 mg/kg,
p.o.) also 30 min after carrageenan administration. Moreover,
the study included influence of complimentary doses of ASA
(0.77 mg/kg, 7.7 mg/kg, and 77.0 mg/kg, p.o.) to proper doses of
OAO-ASA (8) (3.0 mg/kg, 30.0 and 300.0 mg/kg, respectively) or
the interaction between the compound 8 and ASA (200 mg/kg,
p.o.) on anti-inflammatory activity in rats measured also 30 min
after carrageenan administration. The rate of oedema of the two
paws was measured at 1.5, 3.0, 6.0, and 10.0 h after carrageenan
injection using a plethysmometer.
Change of rat’s paw thickness was evaluated using the
following equation:
1G = (Lc − Lw)− (Rc − Rw)
G – value expressing change in paw’s thickness against baseline
(before inflammation)
Lw – left paw’s thickness before carrageenan injection
Rw – right paw’s thickness before carrageenan injection
Lc – left paw’s thickness 1.5, 3.0, 6.0, or 10.0 h after carrageenan
injection
Rc – right paw’s thickness 1.5, 3.0, 6.0, or 10.0 h after
carrageenan injection
Subchronic Effect of OAO-ASA (8)
In the last step of our study, the antinociceptive activity of OAO-
ASA (8) for mice and anti-inflammatory activity of the above
conjugate 8 for rats were evaluated in selected effective dose of
30.0 mg/kg (p.o.) after first and repeated application once a day
during four consecutive weeks.
Measurement of Cytokines Levels in Rats
On the next day after anti-inflammatory activity tests
measurements the drug was given again and 120 min later
rats were sacrificed and the blood was collected. First part
of the blood was centrifuged at 4000 rpm for 15 min and
the serum was separated and stored at −80◦C for further
biochemical measurements. These measurements were done by
means of the ELISA method using commercially available kits
(RayBiotech Inc.). These tests comprised recombinant cytokines
from Escherichia coli and antibodies against rats interleukin 6
(IL-6) and Tumor Necrosis Factor alpha (TNF-α). The results
were calculated based on the absorbance of complex cytokines-
antibodies and concentrations were obtained from model curves
according to producer protocols.
Influence of OAO-ASA (8) on mRNA Levels of Studied
Genes
From the second part of peripheral blood of rats the mononuclear
cells (MNCs) were isolated via a gradient centrifugation
in Ficoll. From the resulting cell pellets a total RNA was
isolated using TriPure Isolation Reagent (Roche) according
to the manufacturer’s protocol. The integrity of RNA was
visually assessed electrophoretically and spectrophotometrically
(BioPhotometer Eppendorf). The 1 µg of total RNA from all
samples was used for reverse transcription into complementary
DNA (cDNA) using Transcriptor First Strand Synthesis Kit
(Roche), according to the manufacturer’s protocol, then were
stored at −20◦C or used directly for quantitative real-time PCR
(qRT-PCR).
The IL-6, TNF-α, Toll-like receptor 1 (TLR-1), and Toll-
like receptor 3 mRNA (TLR-3 mRNA) levels were analyzed
by quantitative real-time PCR using the LightCycler R© TM
Instrument (Roche, Germany) and the LightCycler R© FastStart
DNA Master SYBR Green I (Roche, Germany) according to
the manufacturer’s instructions. All primer sequences were self-
designed using Oligo 6.0 software (National Biosciences) and
verified by the electrophoretical assessment and by melting curve
analysis of each cDNA amplification product. A glyceraldehyde
3-phosphate dehydrogenase gene (GAPDH gene) was used as
a housekeeping gene (endogenous internal standard). Standard
curves were prepared from dilution of cDNA and generated
from a minimum of four data points for each quantified gene.
All quantitative PCR reactions were repeated twice. Data were
evaluated using LightCycler Run 4.5 software (Roche Applied
Science). Each PCR run included a non-template control to detect
potential contamination of reagents.
Statistical Analysis
The data were expressed as means ± SEM and the statistical
comparison of results was carried out using ANOVA followed by
a Duncan post hoc test.
RESULTS
Synthesis of OAO-ASA (8)
The conjugate OAO-ASA (8) was obtained from oxime of
oleanonic acid morpholide (7). The oxime 7 was synthesized as
it is presented in Scheme 1 and with application of procedures
known from our earlier work (Bednarczyk-Cwynar et al., 2015).
First, oleanolic acid (1) was acetylated with a 10-fold excess
of acetic anhydride in dried pyridine. The obtained product,
with a reversibly blocked hydroxyl group at C-3 position (3-
O-acetyloleanolic acid, (2), was subjected to thionyl chloride
action and the resulting 3-O-acetyloleanolic acid chloride (3)
was transformed into 3-O-acetyloleanolic acid morpholide (4)
upon the action of morpholine in dried benzene at room
temperature. The obtained 3-O-acetylmorpholide of oleanolic
acid 4 was hydrolyzed with 5% sodium hydroxide ethanolic
solution with short heating. As spectral data proved, in these
alkaline conditions only the ester bond at the C-3 position
underwent hydrolysis to give product 5. The morpholide of
oleanolic acid with the C-3 carbonyl group (compound 6)
was obtained by oxidation of an appropriate amide with the
free hydroxyl group (derivative 5) with Jones reagent. The 3-
oxoderivative 6 was subjected to reaction with hydroxylamine
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SCHEME 1 | Synthesis of conjugate OAO-ASA (8). Reagents and conditions: (a) pyridine, (CH3CO)2O, rt.; (b) SOCl2, rt.; (c) C6H6, morpholine, rt.; (d) C2H5OH,
KOH, reflux; (e) acetone, Jones reagent, rt.; (f) C2H5OH, NH2OH x HCl, CH3COONa, reflux; (g) dioxane, ASA, DCC, rt.
hydrochloride in ethanol and the resulted oxime 7 was acylated
with ASA in dioxane in the presence of N,N-DCC (Bednarczyk-
Cwynar et al., 2012; Kaminskyy et al., 2012) to give the conjugate
OAO-ASA (8).
Acute Toxicity Test
It was found that acute administration of OAO-ASA (8) to male
mice (n = 5) at the dose of 2.0 g/kg b.w. (p.o.), did not show any
mortality or toxic effects during the next 21 days.
Locomotor Activity Test
The study was performed using five groups of mice (n = 9–
10 in each group) treated with OAO-ASA (8) in doses of 0.3,
3.0, 30.0, and 300.0 mg/kg (p.o.) and control (5% Tween 80).
One-way ANOVA analysis of variance has presented that single
administration of the compound 8 in the above range of doses
has not shown a statistically significant effect on horizontal
locomotor activity in mice [F(4,56) = 3.90; p = 0.007]. The
impact of the individual doses of OAO-ASA (8) on horizontal
locomotor activity revealed that only a dose of 3.0 mg/kg has
increased mobility of the animals during horizontal activity test
(p < 0.05). In addition, a decrease in activity was observed
after administration of 300.0 mg/kg of this compound 8, but the
average value obtained was not significantly different compared
to the control values (p> 0.05; Figure 1).
FIGURE 1 | Dose-dependent effect of OAO-ASA (8) on horizontal
locomotor activity in mice. Number of mice = 9–10 in each group, data are
mean ± SEM, control = mice treated with 5% Tween 80, ∗ = vs. Control,
p < 0.05.
Analgesic Activity – Hot-Plate Test
Dose-Dependent Study
The study was performed using five groups of mice (n = 9–10 in
each group) treated with OAO-ASA (8) in doses of 0.3, 3.0, 30.0,
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and 300.0 mg/kg and control (5% Tween 80). Administration of
conjugate 8 has shown a statistically significant analgesic activity
in the hot-plate test performed on mice [ANOVA main effect
F(4,56)= 53.3, p= 0.000] and has indicated a significant effect of
time on this type of activity [ANOVA, F(4,224)= 4.46; p= 0.002].
The interaction between group and time effect also has shown
high significance [ANOVA II: F(16,224)= 4.96; p= 0.000]. Based
on further analysis performed by a post hoc test, it was found that
there are significant differences in inhibition of the pain response
by OAO-ASA (8) after thermal stimuli (Figure 2). The peak of
analgesic effect of compound 8 was observed after administration
of the compound at a dose of 300.0 mg/kg after 30 min. It was
also found that the analgesic action of conjugate 8 appeared after
using the lowest tested dose (0.3 mg/kg) after 2 h (p < 0.05)
and this particular effect was maintained up to 24 h. However,
OAO-ASA (8) given at a dose of 3.0 mg/kg was active at 0.5 h
after starting the test, and the strongest activity was observed after
2 h, but the effect was not statistically significant at 24th hour of
the experiment. For the analyzed compound 8 in doses of 30.0
and 300.0 mg/kg, the analgesic effect was visible throughout the
course of the study and continued up to 24 h of the experiment
compared to the control values (p< 0.01).
Analgesic Effect of Complimentary Doses of ASA
The study was performed using four groups of mice (n = 9–10
in each group) treated intragastrically with ASA (0.77, 7.7, and
77.0 mg/kg) in complimentary doses to OAO-ASA (8) of 3.0,
30.0, and 300.0 mg/kg (p.o.); referent dose of ASA in 300.0 mg/kg
and control (5% Tween 80). Total variability in the tested doses
for the analgesic effect of complimentary doses of ASA has been
noted [ANOVA: F(3,35)= 9.04; p= 0.000], but has not detected a
statistically significant effect of time on the antinociceptive effect
in the analyzed experimental system [ANOVA: F(4,140)= 0.812;
p = 0.519]. Analyzing the impact of group and time effects,
the occurrence of variation between the values were obtained
[ANOVA II: Interaction F(12,140) = 2.95; p = 0.001]. Further
analysis of ASA complementary doses to conjugate 8 for an
analgesic effect in the mice hot-plate assay has indicated that
only administration of ASA at the dose of 300.0 mg/kg has
shown significant analgesic activity in comparison to the control
group (Figure 3). The effect of ASA at this dose was visible
from 0.5 to 2 h after the application, but no analgesic effect
was observed after 24 h. Also, no significant differences for the
ASA stated in all complementary doses of ASA for the content
of the analyzed compound 8 relative to control values were
observed.
Interaction of OAO-ASA (8) with ASA
The study was performed using 6 groups of mice (n = 9–10 in
each group) treated with OAO-ASA (8) in doses of 0.3, 3.0, 30.0,
and 300.0 mg/kg (p.o.) and ASA in the dose of 300.0 mg/kg,
p.o.; for control purposes the effect of ASA only in the dose
FIGURE 2 | Dose-dependent analgesic effect of OAO-ASA (8) in mice. Number of mice = 9–10 in each group, data are mean ± SEM, control = mice treated
with 5% Tween 80, ∗ = vs. proper Control, p < 0.05.
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FIGURE 3 | Effect of complimentary dose of ASA on analgesic action of OAO-ASA (8) in mice. Number of mice = 9–10 in each group, control = mice
treated with 5% Tween 80, data are mean ± SEM, ∗ = vs. proper Control, p < 0.05.
of 300.0 mg/kg was also measured in comparison to control
rats (5% Tween 80). When analyzing the effect of the co-
administration of OAO-ASA (8) and ASA for antinociceptive
activity in the hot-plate assay, the existence of a general statistical
variation in experimental system has been confirmed [ANOVA,
effect of group, F(5,53) = 35.7; p = 0.000], as well as the
significant effect of time on the antinociceptive activity [ANOVA:
F(4,212) = 51.5; p = 0.000]. The interaction of these two effects
(i.e., the effect of group and time) showed the existence of
significant differences between these two parameters [ANOVA:
interaction F(20,212) = 3.827; p = 0.000]. Post hoc analysis has
shown the presence of the antinociceptive effect of ASA given at
a dose of 300.0 mg/kg in the range of 0.5–2 h from the start of the
study (p< 0.05), but after 24 h, there was no significant difference
in comparison to the control value (Figure 4). For the combined
administration of the examined substance OAO-ASA (8) and
ASA over the range of doses used, the significant differences
between obtained values and control at the time 0.5, 1, 1.5, and
2 h were noted. After 24 h, the effect after co-administration of
ASA and the compound 8 at doses of 0.3–30.0 mg/kg was not
significantly different from that of the control group administered
with vehicle alone, only in the highest dose of the OAO-ASA (8)
co-administered with ASA has differed significantly from control
values (p < 0.05). It has been noted that conjugate 8 in a dose of
300.0 mg/kg significantly increased the strength and prolonged
the duration of antinociceptive action of ASA in each of the time
points tested; while at a dose of 3.0 mg/kg the increased potency
of ASA after combined administration was seen only in 0.5, 1, and
1.5 h of the experiment.
Interaction of OAO-ASA (8) with MF
The study was performed using six groups of mice (n = 9–10
in each group) treated with OAO-ASA (8) in doses of 0.3, 3.0,
30.0, and 300.0 mg/kg (p.o.) and MF in a dose of 5.0 mg/kg
(s.c.); for comparative purposes MF in a dose of 5.0 mg/kg and
proper control group were used (5% Tween 80; 0.9% NaCl). Study
on the combined administration of the examined compound 8
and MF was able to show the overall variability between means
[ANOVA, main effect, F(5,54)= 10.2; p= 0.000], and highlighted
the importance of the effect of time on the course of the analgesic
effect [ANOVA, effect of time, F(4,216) = 64.6; p = 0.000]. The
interaction of these two effects (i.e., the effect of group and time)
showed the existence of significant differences between these two
parameters [ANOVA, interaction F(20,216) = 6.02; p = 0.000].
Post hoc analysis revealed the analgesic effect of MF after 0.5,
1, and 1.5 h of the test when compared with the control group
(p< 0.05); whereas after 2 and 24 h showed no significant effects
(Figure 5). Co-administration of MF and OAO-ASA (8) in a
dose of 0.3 mg/kg has shown a significant analgesic effect that
lasted for 2 h from the start of the test, and in 0.5 h of the
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FIGURE 4 | Effect of OAO-ASA (8) on antinociceptive activity of ASA (300.0 mg/kg p.o.) in mice. Number of mice = 9–10 in each group, data are
mean ± SEM, control = mice treated with 5% Tween 80, ∗ = vs. proper Control, p < 0.05, + = vs. ASA 300 mg/kg, p.o., p < 0.05.
test significantly increased the analgesic activity of MF. For the
compound 8 in the doses of 3.0 and 300.0 mg/kg combined
with MF, the analgesic effect was shown in all tested intervals
except for 24 h. The least effective was administration of MF
with conjugate 8 at a dose of 30.0 mg/kg, where no significant
antinociceptive activity was shown in any of the time points
tested. Moreover, it has been found that the combination of the
OAO-ASA (8) in a dose of 3.0 mg/kg with MF significantly
lowered pain response at 0.5 and 1 h when compared with MF.
There were no significant differences as compared to combined
administration to the mean values of MF at other points of
time.
Interaction of OAO-ASA (8) with NL
The study was performed using four groups of mice (n= 9–10 in
each group) treated with OAO-ASA (8) in a dose of 30.0 mg/kg
without and with NL in a dose of 3.0 mg/kg (s.c.); NL in
3.0 mg/kg alone and control group (5% Tween 80; 0.9% NaCl).
The experimental system demonstrated the existence of variation
between the means [ANOVA main effect, F(3,37) = 31.9;
p = 0.000] and indicated the significance of the effect of time
[ANOVA effect of time F(4,148) = 8.38, p = 0.000]. Analysis of
the interaction of both factors studied in this test indicated the
importance of the action of both effects [ANOVA, interaction
F(12,148) = 2.14; p = 0.018]. Further detailed analysis allowed
to determine that administration of NL in all time points
did not show significant analgesic activity compared to the
corresponding control values (Figure 6). It was found that for the
entire test time interval, OAO-ASA (8) given with and without
NL resulted in statistically significant values when compared
with corresponding control values (p ≤ 0.01). No significant
differences were detected in addition to the analgesic effect
between the group receiving conjugate 8 and the group receiving
the combination of the tested compound 8 with NL (p> 0.05).
Anti-inflammatory Effects
Dose-Dependent Study
The study was performed using five groups of rats (n = 8 in
each group) treated with OAO-ASA (8) in doses of 0.3, 3.0,
30.0, and 300.0 mg/kg and control (5% Tween 80). It was noted
that administration of the compound 8 showed a statistically
significant anti-inflammatory activity in the experimental system
used [ANOVA, the main effect, F(4,35) = 4.48; p = 0.000; effect
of time F(4,140) = 81.5, p = 0.000]. The interaction of both
factors indicated the importance of the action of both [ANOVA,
interaction F(16,140)= 6.91, p= 0.000]. Further post hoc analysis
allowed to determine that the anti-inflammatory effect in relation
to the control group. This was characterized by administration
of the analyzed compound (triterpene 8) at a dose of 0.3 mg/kg
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FIGURE 5 | Effect of OAO-ASA (8) on analgesic activity of MF (5.0 mg/kg, s.c.) in mice. Number of mice = 9–10 in each group, data are mean ± SEM,
control = mice treated with 5% Tween 80, 0.9% NaCl, ∗ = vs. proper Control, p < 0.05, + = vs. MF 5.0 mg/kg, s.c., p < 0.05.
after 6 h (p < 0.05), for a dose of 3.0 mg/kg was of weak
significance (p = 0.051) at the third hour after start of the test,
but statistically significant effect was observed at sixth hour of
the study (p ≤ 0.05), for a dose of 30.0 mg/kg, this effect already
appeared in third hour (p < 0.05) and was still visible after 6 h
(p< 0.01) when compared with the corresponding control values
(Figure 7).
Anti-inflammatory Effect of Complimentary Doses of
ASA
The study was performed using four groups of rats (n = 8 in
each group) treated with ASA (7.7 and 77.0 mg/kg, p.o.) in
complimentary doses to OAO-ASA (8): 30.0 and 300.0 mg/kg;
ASA in a referent dose of 200.0 mg/kg and control (5% Tween 80).
Analysis of variance used during the experiment has indicated
a statistically significant anti-inflammatory effect either for a
group [ANOVA effect of group F(3,28) = 8.99; p = 0.000]
and for time as a factor associated with anti-inflammatory
effect in this experimental system [ANOVA: F(4,112) = 68.6;
p = 0.000]. It has been shown that the interaction of both of
these factors are also statistically significant [ANOVA, interaction
F(12,122) = 6.806; p = 0.000]. Detailed analysis of the post hoc
test showed that only ASA significantly reduced the carrageenan-
induced edema at first, third hour (p < 0.05) and sixth hour of
observation (p < 0.01) when compared with respective control
values (Figure 8).
Interaction of OAO-ASA (8) with ASA
The study was performed using five groups of rats (n = 8 in
each group) treated with OAO-ASA (8) in doses of 0.3, 3.0,
and 30.0 mg/kg and ASA in a dose of 200.0 mg/kg; referent
single dose of ASA in 200.0 mg/kg and control (5% Tween 80).
The following experimental system was found to have significant
variability in the results of the performance of the combined
administration of ASA and OAO-ASA (8) in rats [ANOVA, main
effect, F(4,35)= 34.2; p= 0.000]. It also indicated the importance
of activity of time after the administration of carrageenan and
the compounds [ANOVA, effect of time F(4,140) = 284.3;
p = 0.000]. Analysis of the interaction of both factors pointed
at the significance of the action of both [ANOVA II interaction
F(16,140) = 20.8; p = 0.000]. Post hoc analysis showed that
both, the single ASA administration and conjugate 8 with ASA
demonstrated the anti-inflammatory effect in a range 1–10 h
when compared with the proper control values (p < 0.01;
Figure 9). It was also shown that the effects did not differ
between the values for combined administration of OAO-ASA
(8) in all doses with ASA and the single ASA administration
(p> 0.05).
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FIGURE 6 | Effect of OAO-ASA (8) on analgesic activity of NL (3.0 mg/kg, s.c.) in mice. Number of mice = 9–10 in each group, data are mean ± SEM,
control = rats treated with 5% Tween 80; 0.9% NaCl, ∗ = vs. proper Control, p < 0.05.
Subchronic Analgesic and Anti-inflammatory Activity
of OAO-ASA (8)
The study was performed using two groups of mice (n = 10 in
each group) treated with OAO-ASA (8) in a dose of 30.0 mg/kg
and analgesic activity was assessed after first and after 28
applications of triterpene 8. Analysis of variance used during
the experiment has indicated a statistically significant analgesic
effect either for a group [ANOVA, main effect, F(3,36) = 76.2;
p= 0.000] and for time as a factor associated with this activity in
the experimental model [ANOVA, effect of time, F(4,144)= 25.0;
p = 0.000]. Post hoc analysis showed that both, after single and
subchronic administration OAO-ASA (8) produced significant
analgesic activity (p < 0.05) in time range of 0.5–2 h when
compared with proper control values (Figure 10). However, due
to the fact that obtained values did not differ between each other
for the time, therefore an occurrence of tolerance for analgesic
activity might be excluded.
The study for the assessment of the effect of subchronic
treatment on anti-inflammatory activity of OAO-ASA (8) was
performed using two groups of rats (n= 10 in each group) treated
with the triterpenic conjugate 8 in a dose of 30.0 mg/kg and
the activity was measured after first and after 28 applications of
OAO-ASA (8). Analysis of variance used during the experiment
has indicated a statistically significant analgesic effect either for
a group [ANOVA, main effect, F(3,36) = 23.3; p = 0.000]
and for time as a factor associated with this activity in the
experimental model [ANOVA, effect of time, F(4,144) = 168.1;
p = 0.000]. Post hoc analysis showed that both the single and
subchronic conjugate 8 administration significantly reduced the
carrageenan-induced edema in the range of 1–10 h of observation
(p < 0.05) when compared with the proper control values
(Figure 11). Similarly, as for the analgesic activity of OAO-ASA
(8) there were no differences between the values for single and
subchronic treatments in the time points (1–10 h), therefore
effect of tolerance for the anti-inflammatory activity should be
excluded.
Peripheral Cytokines Concentrations and mRNA
Expression Changes
A one-way ANOVA revealed significant difference between the
groups of rats in the IL-6 mRNA levels [F(1,18)= 11.7; p< 0.001;
Table 1]. Subchronic treatment with OAO-ASA (8) led to a
significant decrease of the cytokine concentration compared
to the control group. On the contrary, the one-way ANOVA
showed insignificant difference between the groups in the TNF-
α levels [F(1,17) = 0.953; p > 0.05; Table 1], however, there
was a tendency to lower the cytokine concentration in rats
after OAO-ASA (8) treatment. Statistical analysis of IL-6 mRNA
expression showed significant difference between the groups
[ANOVA: F(1,15) = 4.90; p < 0.05; Table 1] and the subchronic
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FIGURE 7 | Dose-dependent anti-inflammatory effect of OAO-ASA (8) in rats. Number of rats = 8 in each group, data are mean ± SEM, control = rats
treated with 5% Tween 80, ∗ = vs. proper Control, p < 0.05.
OAO-ASA (8) administration lowered the mRNA expression
of this cytokine. Similarly, the ANOVA revealed significant
differences between the groups of rats in the TNF-α mRNA
expression [F(1,18) = 14.1, p < 0.01; Table 1], but OAO-ASA
(8) administration caused a strong increase of the measured
parameter. Additionally, effect of OAO-ASA (8) on the mRNA
expression of TRL-1 and TLR-3 was measured. It was found that
there was a significant difference between the groups for the TRL-
1 mRNA expression [F(1,18) = 5.14; p < 0.05; Table 1] and
OAO-ASA (8) administration showed an increased transcription
level compared to the control group. On the contrary, a one-way
ANOVA revealed insignificant difference between the groups in
the TLR-3 mRNA expression [F(1,18)= 0.117; p> 0.05; Table 1].
DISCUSSION
The triterpenic conjugate of oxime of oleanolic acid morpholide
(7) and ASA, named as OAO-ASA (8) was obtained in a simple
reaction of the above oxime (7) and ASA in dried dioxane in the
presence of N,N-DCC as condensing agent. Stirring of these three
reagents in dioxane at room temperature led only to one product,
as TLC control proved. The received crude product 8 have not
formed crystals and was purified by re-precipitation with water
from ethanolic solution.
The analysis of 1H and 13C NMR spectra of the obtained
product OAO-ASA (8) proved structure of this compound.
Signals derived from aromating ring of ASA were observed
at δ 7.97 (1H, dd), 7.57 (1H, td), 7.32 (1H, td), and 7.13
(1H, dt) ppm. Signal from the acetoxy function of ASA within
conjugate 8 was observed as singlet at 2.34 ppm. The morpholine
ring protons of OAO-ASA (8) gave strong multiplet that was
present at 3.70–3.58 ppm (8H). In 13C NMR seven characteristic
quaternary signals were observed, at δ176.3, 175.1, 169.6, 162.0,
150.6, 144.8, and 122.8 ppm. First and second of them (176.3
and 175.1 ppm) were attributed to the C-3 and C-28 atoms
within the molecule of OAO-ASA (8) (Bednarczyk-Cwynar et al.,
2015), respectively; third of them, present at δ 169.6 ppm derived
from acetoxyl (CH3COO–) within ASA; the next one (at δ
162.0 ppm) pointed at the carboxyl function linked to nitrogen
atom (–COON=). The two further quaternary signals, present
at 150.6 and 122.8 ppm, were assigned to ASA ring and the
last quaternary carbon, observed at 144.8 ppm, derived from C-
13 atom (Bednarczyk-Cwynar et al., 2015). The remaining four
tertiary aromatic signals were observed at δ 133.7, 131.2, 125.9,
and 124.0 ppm. The morpholine ring signals were present at
typical values of chemical shifts: δ 66.9 × 2, 47.4 and 47.2 ppm
(Bednarczyk-Cwynar et al., 2015).
In pharmacological part of our research, at first, the acute
toxicity of OAO-ASA (8) was assessed. The results allowed
Frontiers in Pharmacology | www.frontiersin.org 11 July 2016 | Volume 7 | Article 202
fphar-07-00202 July 9, 2016 Time: 15:18 # 12
Bednarczyk-Cwynar et al. Pharmacological Activity of Oleanolic Acid Derivatives
FIGURE 8 | Effect of complimentary dose of ASA on anti-inflammatory activity of OAO-ASA (8) in rats. Number of rats = 8 in each group, data are
mean ± SEM; control = rats treated with 5% Tween 80, ∗ = vs. proper Control, p < 0.05.
maintaining that the analyzed compound 8 shows low toxicity
(LD50 > 2 g/kg) and belongs to Toxicity Class 1 (data not shown).
This is in agreement with the results of other studies that this class
of compounds possesses rather low toxicity (Singh et al., 1992;
Liu, 1995; Bednarczyk-Cwynar et al., 2012).
In the next part of the study, we decided to check whether
OAO-ASA (8) can affect locomotor activity of mice, since an
eventual sedation (expressed by lowering of animals’ activity)
can give false positive results in hot-plate experiment. The test
is sometimes performed also in order to answer whether or not a
new substance has an impact on the behavior of animals coupled
with some aspects of cognition and fear (Piazza et al., 1989;
Cools and Gingras, 1998). It was found that OAO-ASA (8) only
in the dose of 3.0 mg/kg increased the horizontal locomotor
activity, whereas, in the rest of doses, it did not affect this
paradigm, therefore the risk of sedation can be excluded from
OAO-ASA (8) pharmacological profile. Generally the results are
in line with observations coupled with pharmacological profile of
many triterpenes obtained by other authors (Oliveira et al., 2005;
Soldi et al., 2008; Marcon et al., 2009; Bednarczyk-Cwynar et al.,
2012).
It was observed that OAO-ASA (8) exhibited antinociceptive
effect in the applied model using the hot-plate test, which
represents a tool for the study of supraspinal pain. The test
is generally used for centrally acting analgesic drugs such as
morphine, whereas for the peripherally acting analgesics is rather
ineffective (Matthes et al., 1996; Milano et al., 2008). Moreover,
the test was performed in several other studies of derivatives of
oleanolic acid (Jung et al., 2005; Otuki et al., 2005a; Bednarczyk-
Cwynar et al., 2012). Since there are opinions that oleanolic acid
and its some derivatives produce the antinociceptive effect via
opioid mechanism of action (Maia et al., 2006b; Park et al., 2013),
therefore the next stage of the experiment was to test a possible
interaction with opioid receptor agonist MF and pure antagonist
of opioid receptors NL. Suggesting from our previous studies MF
was selected for this purpose in a dose of 5.0 mg/kg administered
subcutaneously (Siekierkowska et al., 2007) and was in the range
of doses used by other investigators (Maldonado et al., 1998;
Sammons et al., 2000; Tsai et al., 2000). In the same manner
NL was administered, as an antagonist of the opioid receptors
in a dose of 3.0 mg/kg (Bodnar et al., 1978; Mena et al., 1996;
Li et al., 2004; McGaraughty et al., 2005). The study showed
the interaction between the tested OAO-ASA (8) and opioid
agonist, since especially in the dose of 30.0 mg/kg the conjugate
8 significantly decreased central effects of analgesia induced by
opioid, but there was no effect on test values in mice after a
combined application with NL. The results rule rather analgesic
activity of the tested compound 8 through the mechanism of
opioid proposed by some authors (Maia et al., 2006b; Park et al.,
2013), related to the increased release of endogenous opioid or
agonist effects on opioid receptors. Therefore, it is in line with
the results of Otuki et al. (2005a) showing that some oleanolic
acid derivatives did not express centrally mediated analgesic
activity.
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FIGURE 9 | Effect of OAO-ASA (8) on anti-inflammatory activity of ASA (200.0 mg/kg, p.o.) in rats. Number of rats = 8 in each group, data are
mean ± SEM, control = rats treated with 5% Tween 80, ∗ = vs. proper Control, p < 0.05.
The antinociceptive analgesic activity of the compound 8
after single administration was maintained up to 24 h from
the start of the test on the same level especially in the dose
of 30.0 mg/kg, but it lasted longer than the effect of reference
substance ASA (300 mg/kg, p.o.) in the same test. It should
be stressed that ASA also exhibits an antinociceptive effect
in the hot-plate test in rodents (Heidari et al., 2004). It was
observed the strongest activity of the compound 8 (tmax) for
30 min of the administration. However, the possible mechanism
of the compound 8 for its antinociceptive activity was rather
similar to ASA action, since testing the compound OAO-ASA
(8) interaction with ASA, only in the lowest dose there was no
synergistic effect on the activity of ASA model used, while in the
rest of doses a significant effect of synergistic interaction with
ASA was found.
In order to determine the possible contribution of ASA
activity released from the test compound 8 in rodents, the
use of ASA in complimentary doses to its presence in OAO-
ASA was performed. The conducted experiments generally
indicated that ASA in complementary doses to the doses used
for OAO-ASA (8) did not affect the analgesic activity. It
shows that rather the whole molecule is responsible for the
analgesic effect of the tested compound 8, however, it cannot
be excluded that the summarizing effect is produced by ASA
released from the compound 8 and the rest of triterpene
derivative. To test this hypothesis more detailed study should be
performed.
In a next step, we decided to evaluate the dosage-dependent
effects of the OAO-ASA (8) for the its anti-inflammatory
activity in the carrageenan test. The results has proven to
be significant relative to the control rats, which enabled the
determination of dose-effect. The strongest effect of OAO-
ASA (8) was observed in the dose of 30.0 mg/kg both for
the analysis of individual time points, and the same dose-
effect was described shape of an inverted “U.” The results
are in line with studies on anti-inflammatory activity of
some oleanolic acid derivatives (Otuki et al., 2005b; Medeiros
et al., 2007; Chung et al., 2008; Preethi et al., 2009). It can
speculate that compound 8 probably inhibits COX-2 activity
and production of PGE2. It is due to the fact that after
60 min from carrageenan administration the prostaglandin phase
of inflammation appears (Al-Majed et al., 2003). Moreover,
from many studies concerning mechanism of anti-inflammatory
action of oleanolic acid derivatives it is known that the effects are
on transcriptive level via NF-κB which is coupled with COX-2
inhibition (Medeiros et al., 2007; Chung et al., 2008; Martinez-
Gonzales et al., 2008; Nihiem et al., 2011; Jung et al., 2013; Kim
et al., 2014).
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FIGURE 10 | Comparison of analgesic activity of OAO-ASA (8) after single and subchronic administration in mice. OAO-ASA (8) treatment with a dose of
30 mg/kg, p.o. Number of mice = 10 in each group, data are mean ± SEM, control – mice treated with 5% Tween 80, ∗ = vs. proper Control, p < 0.05, + = vs.
proper OAO-ASA (8) single, p < 0.05.
In order to determine the possible contribution of ASA anti-
inflammatory activity released from the test compound 8 in
rats, the use of ASA in complimentary doses to its presence
in OAO-ASA was performed. It shows that rather the whole
molecule is responsible for the anti-inflammatory effect of the
tested compound 8, however, it cannot be excluded that the
summarizing effect is produced by ASA released from the
compound 8 and the rest of triterpene derivative. To test this
hypothesis more detailed study should be performed. However,
the OAO-ASA (8) anti-inflammatory mechanism of action
is probably more complicated since there was no synergistic
interaction between the compound 8 and ASA.
Basing on the obtained results of the evaluation of analgesic
activity, with the assessment of locomotor activity, as well as
the evaluation of anti-inflammatory action, it was concluded
that the best activity of OAO-ASA (8) was obtained in a dose
of 30.0 mg/kg which qualified for further study concerning the
phenomenon of tolerance to analgesic and anti-inflammatory
activities. Both the analgesic action and anti-inflammatory effects
did not find any statistically significant differences in the activity
of triterpene 8 after single or subchronic administration. That
meant that the scheduled test compound OAO-ASA (8) did not
show tolerance to suppress pain and swelling, at least during the
4-week treatment. The results are in line with the observation
found by Ferreira et al. (2000) that the methanolic extract from
Epidendrum mosenii contained two triterpenes (pholidotin and
24-methylenecycloartenol) given daily for to seven consecutive
days did not develop tolerance to its antinociceptive activity in
the hot-plate test.
After 4 weeks of treatment with OAO-ASA (8) the
concentration of selected proinflammatory cytokines, i.e., TNF-
α and IL-6 in serum as well as the mRNA expression for
the TNF- α, IL-6, TLR-1, and TLR-3 genes in lymphocytes
were performed. The study of TLR-3 mRNA expression was
chosen because of the widely speculations among researchers
concerning a significance of these receptors in the development
of subchronic pain (Qi et al., 2011; Qian et al., 2011; Liu et al.,
2012). It is known that TLR-3 is localized in astrocytes, microglia,
dendritic cells and blood cells, including B lymphocytes, while
TLR-1 is on surface of phagocytic cells (macrophages) and
monocytes (Hornung et al., 2002; Akira, 2003; Nicotra et al.,
2012). Although the main role of TLR-1 is to response to bacterial
infection and participation in the resistance (Peng and Zhang,
2014), we decided to check its possible effect of subchronic
OAO-ASA (8) administration on the carrageenan-induced
inflammation. It is known that the carrageenan induces induce
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FIGURE 11 | Comparison of anti-inflammatory activity of OAO-ASA (8) after single and subchronic administration in rats. OAO-ASA (8) treatment with a
dose of 30 mg/kg, p.o. Number of rats = 10 in each group, data are mean ± SEM, control = rats treated with 5% Tween 80, ∗ = vs. proper Control, p < 0.05.
TABLE 1 | Interleukin 6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) serum levels and IL-6, TNF-α, TLR-1, and TLR-3 mRNA expression of rats
subchronically treated with OAO-ASA (8).
Groupn Serum concentration (pg/ml) mRNA expression∗ (%)
IL-6 TNF-α IL-6 TNF-α TLR-1 TLR-3
Control 55.4 ± 1.6 1494 ± 332 100 ± 15 100 ± 7 100 ± 10 100 ± 13
OAO-ASA (8) 9.3 ± 0.8∗∗ 1099 ± 201 60 ± 5∗∗ 11 ± 29∗∗ 138 ± 13∗∗ 108 ± 19
TLR-1, TLR-3 = Toll-like receptor 1, Toll-like receptor 3, values are means ± SEM, n = number of animals: 10, ∗ = values expressed as a ratio: the gene/GAPDH,
control = rats treated with 5% Tween 80, OAO-ASA (8) = rats treated with OAO-ASA (8) (dissolved in 5% Tween 80) in the dose of 30 mg/kg (p.o.) for 4 weeks, ∗∗ = vs.
control, p < 0.05.
an inflammatory response via toll-like receptors especially TLR-4
(Bhattacharyya et al., 2008). Moreover, there is report that some
triterpenes (i.e., glycyrrhizin) strongly attenuated inflammatory
responses induced by TLR-3 ligands (Schrofelbauer et al.,
2009).
The resulting phenomena shows that the profile of OAO-
ASA (8) expresses its analgesic activity rather not via opioid
mechanisms, and it is probably a component of its anti-
inflammatory effect. It appears that it correlates in part with
inhibition of proinflammatory effects of IL-6 (Scheller et al.,
2011), in response to induced inflammation, both at the protein
level as the level of mRNA expression of this cytokine. However,
the anti-inflammatory properties of the analyzed compound
(OAO-ASA, 8) are not clear because although there was a
tendency to lower TNF-α level, however, at the level of mRNA
expression of the cytokine, opposite results were obtained.
Similarly, it should be interpreted impact of the analyzed
compound 8 on the expression of TLR-1, which was elevated due
to the administration of the compound 8 without affecting the
TLR-3 gene expression.
Although sometimes a lack of correlation between the results
at the formation of the protein and transcriptional occurs and
reflects the complex interaction at the level of transcription and
translation of particular substance of natural origin (Oz˙arowski
et al., 2013, 2015; Mikołajczak et al., 2015), clearly establish the
profile of anti-inflammatory OAO-ASA (8) and the mechanisms
responsible for this is not possible on the basis of the obtained
results.
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CONCLUSION
The obtained results regarding the analgesic and anti-
inflammatory activity of new conjugate of oleanolic acid
derivative and acetylsalicylic acid (OAO-ASA, 8) is interesting,
but for explanation of its mechanism of action, more detailed
studies are necessary.
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